H19 is an oncofetal RNA expressed in the developing embryo as well as in bladder, breast, gastric, pancreatic, hepatocellular, and prostate cancers. Recent studies have shown that H19 enhances cancer invasion and metastasis; however, its roles in cancer remain controversial. In the current study, H19 exhibited the second largest increase (82.4-fold) and represented the only non-protein coding gene among 11 genes identified that were elevated over 10-fold in lung-metastasisderived pancreatic cancer cells compared with their parental cells using a mouse metastatic model. Subsequently, we further clarified the roles of H19 in pancreatic cancer growth and metastasis using in vitro and in vivo techniques. In situ hybridization showed that H19 was detected in 23 of 139 invasive ductal carcinomas (17%), and that H19 expression positively correlated with higher histological grades (P < 0.0001). Overexpression of H19 in PANC-1 pancreatic cancer cells induced higher motilities, whereas H19 inhibition using shRNA and siRNA showed opposite results; however, cell growth rates were not impacted. Intravenous injection of H19 shRNA vector-transfected PANC-1 cells yielded marked inhibition of metastasis in the liver and lungs of immunodeficient mice. These findings suggest that H19 has important roles in pancreatic cancer metastasis, and that inhibition of H19 represents a novel candidate for pancreatic cancer therapy.
Surgical resection, chemotherapy, and radiotherapy have been employed as treatment options for pancreatic cancer. However, the most recent 5-year survival rate for patients with pancreatic cancer is only 8% [1] . Pancreatic cancers readily metastasize to the other organs at the early stage of the cancer and the recurrence rate after surgery is high. Therefore, novel treatment strategies are required to improve the remission and cure rates of this devastating disorder.
According to the central dogma theory of biology, RNA constitutes the intermediary between DNA and protein.
However, recent genome-wide transcriptome studies have identified that almost all of the human genome is transcribed and produces a large number of non-coding RNAs (ncRNAs) including both small ncRNAs and long ncRNAs (lncRNAs) [2] [3] [4] . Small ncRNAs have been defined as a ribonucleotide smaller than 200-mers including small interfering RNAs (siRNAs), microRNAs, piwi-interacting RNAs, and small nuclear RNAs [5] . Conversely, lncRNAs comprise mRNA-like transcripts longer than 200 ribonucleotides lacking significant open reading frames [2, 3, 6] . The expression and roles of small ncRNAs have been studied intensively in cancer and have demonstrated that small ncRNAs are involved in carcinogenesis. Recently, accumulating evidence suggests that lncRNAs have crucial roles in carcinogenesis, and in the growth and metastasis of various types of cancer; however, the detailed mechanisms remain unclear [2, 3, 5, 6] .
We previously established a novel pancreatic cancer cell line (PANC-lung1 cells) from lung metastatic lesions using super immunodeficient NOD/Shi-scid, IL-2Rγnull (NOG) mice [7, 8] . PANC-lung1 cells exhibited a higher metastatic ability than the parental PANC-1 cells both in vitro and in vivo. To clarify the mechanisms of pancreatic cancer metastasis, we compared the RNA expression levels of the two cell lines using DNA microarray analysis and identified that H19, a lncRNA, represented the highest-expressing ncRNA in metastasis-derived PANC-lung1 cells.
H19 is known as an imprinted RNA that is transcribed exclusively from the maternal allele and also as an oncofetal RNA that is expressed in the developing embryo, as well as in some types of tumors [9, 10] . Recent evidence has shown that H19 enhances invasion and metastasis in bladder cancer [11] , glioma [12] , breast cancer [13] , gastric cancer [14] , and pancreatic cancer [15] , whereas it suppresses the aggressiveness of hepatocellular carcinoma [16] and prostate cancer [17] .
In the current study, we report that inhibition of H19 decreased the metastasis of pancreatic cancer in vivo, indicating that H19 represents a novel candidate for targeted pancreatic cancer therapy.
Materials and methods

Materials
The following were purchased for this study: anti-human leukocyte antigen (HLA) class I-A, B, and C antibody (clone EMR8-5) from Hokudo Co., Ltd (Tokyo, Japan); pancreas tissue microarrays (PA1001, PA1921, and PA2081a) from Biomax, Inc. (Rockville, MD); Histofine mouse stain kit from Nichirei (Tokyo, Japan); TaqMan Fast Universal PCR Master Mix and TaqMan Gene Expression Assays for H19 (Hs00262142_g1) and 18 S rRNA (Hs03928990_g1vv), and siRNAs targeting human H19 (siH19-A, n272453; siH19-B, n272446) and negative control siRNA (Silencer select Negative control 2), as well as pcDNA3.1(−) vector from Life Technologies Corporation (Carlsbad, CA); FuGene HD transfection reagent from Roche Diagnostics (Mannheim, Germany); TransITsiQUEST Transfection Reagent from Mirus Bio LLC (Madison, WI); Low Input Quick Amp Labeling Kit, Agilent human 44k oligonucleotide microarray, and Agilent Gene Expression washing buffer from Agilent Technologies (Santa Clara, CA); Qiagen RNeasy Mini kit from Qiagen (Hilden, Germany); QuantiGene ViewRNA ISH Tissue 2-Plex Assay Kit, human H19 lncRNA probe set (catalog number VA1-13208-01), human ubiquitin-C mRNA probe set (catalog number VA6-10503-01), and Escherichia coli K12 dapB mRNA probe set (catalog number VF1-10272-06) from Affymetrix, Inc. (Santa Clara, CA); FastPure RNA kit and pBAsi-hU6 Neo DNA vector from TaKaRa Bio (Shiga, Japan); WST-8 cell counting kit, gemcitabine hydrochloride, and 5-fluorouracil (5-FU) from Wako Pure Chemical Industries (Osaka, Japan); cell culture insert (8 μm pore size) from BD Biosciences (Franklin Lakes, NJ); paclitaxel from Taiho Phamaceutical Co. (Tokyo, Japan), and Diff-Quick staining kit from Sysmex Corp. (Kobe, Japan). All other reagents were purchased from SigmaAldrich Corporation (St. Louis, MO).
Cell culture
Human pancreatic ductal carcinoma (PDAC) cell lines PK-1, AsPC-1, PK-45P, PK-45H, PK-9, PK-8, PANC-1, and MIAPaCa-2 were obtained from the Cell Resource Center for Biomedical Research, Institute of Development, Aging and Cancer, Tohoku University (Sendai, Japan), and human immortalized pancreatic ductal epithelial cell lines HPDE4 and HPDE6 were obtained from Dr. Ming-Sound Tsao (Ontario Cancer Institute, Toronto, ON, Canada). These cells were grown in RPMI 1640 medium containing 10% fetal bovine serum (FBS) at 37°C under a humidified 5% CO 2 atmosphere. The Capan-1 human PDAC cell line was purchased from American Type Culture Collection (Manassas, VA) and the cells were cultured in RPMI 1640 medium with 15% FBS.
Cell lines from PANC-1 cell-derived liver and lung metastases
Cell lines from liver and lung metastases derived from PANC-1 cells were established as previously reported [7] . Briefly, NOD/Shi-scid, IL-2ã null (NOG; Central Institute for Experimental Animals, Kanagawa, Japan) mice were administered a single intrasplenic injection of 1 × 10 5 PANC-1 cells. Five to 8 weeks later, the involved liver and lungs of the mice were removed and fragments of the metastatic foci were dispersed in a culture medium (PANCliver1, PANC-liver2, PANC-lung1, and PANC-lung2). As negative control cells, the tumor fragments from subcutaneous injection of PANC-1 cells were dispersed in a medium containing antibiotics and two cell lines were established (PANC-skin A and PANC-skin B cells). Metastatic PANC-1 cells from the liver or lungs and subcutaneously injected PANC-1 cells were confirmed as being of human origin using PCR with human-or mouse-specific mitochondrial gene primers as previously described [7] . All animal experiments were carried out according to the institutional animal care guidelines of the Nippon Medical School Animal Ethical Committee (No. 26-109).
DNA microarray analysis
PANC-1 and PANC-lung1 cells were plated at a density of 2.5 × 10 5 cells in a 60 mm dish. After 3 days, total RNA was isolated using the FastPure RNA kit. For DNA microarray analysis, 50 ng RNA from these cells was labeled using the Low Input Quick Amp Labeling Kit. Labeled RNA was further purified using the Qiagen RNeasy Mini kit. Labeled cRNA was hybridized to the Agilent human 44k oligonucleotide microarray and washed using Agilent Gene Expression washing buffer. Microarrays were scanned in an Agilent DNA Microarray Scanner and expression data were obtained using Agilent Feature Extraction software. Data were analyzed using Gene Spring GX version 11 (Agilent Technologies).
Quantitative reverse transcription-PCR
Quantitative reverse transcription-PCR (qRT-PCR) was performed with the StepOnePlus PCR system (Life Technologies) using TaqMan Fast Universal PCR Master Mix and TaqMan Gene Expression Assays for H19 and 18S rRNA. qRT-PCR was performed according to the manufacturer's protocol. qRT-PCR results were expressed as the ratio of target to 18S rRNA, the latter serving as an internal standard. Gene expression levels were measured in triplicate using qRT-PCR.
Branched DNA in situ hybridization
Branched DNA in situ hybridization (bDNA ISH) was performed according to the protocol of the QuantiGene ViewRNA ISH Tissue 2-Plex Assay Kit using normal, inflammatory, and neoplastic pancreas tissue microarrays [18] . Briefly, the pancreas microarray tissue sections purchased from Biomax Inc. were re-fixed in 10% formaldehyde/phosphate-buffered saline (PBS) to equalize tissue conditions, deparaffinized, boiled in Pretreatment Solution (1:100) for 10 min at 90-100°C, and digested with protease (1:100) for 10 min at 40°C. Sections were hybridized with either the H19 probe set, ubiquitin-C probe set (positive control), or E. coli K12 dapB probe set (negative control) diluted 1:40 for 2 h at 40°C. The H19 probe binds to human H19 but does not react with mouse H19. After washing, the sections were hybridized with PreAmplifier Mix for 25 min at 40°C, washed, hybridized with Amplifier Mix for 15 min at 40°C, washed, and finally hybridized with Label Probe conjugated to alkaline phosphatase (1:1000) for 15 min at 40°C. After washing, the sections were incubated with either the fast red substrate and counterstained with hematoxylin.
Generation of stable H19-overexpressing or H19-shRNA-expressing PANC-1 cells
The H19 full-length cDNA (2.3 kb) cloned into pcDNA3.1 (−) vector (a generous gift from Dr. Eric Adriaenssens, Science and Technology, Lille 1 University, France) and empty vector were transfected into PANC-1 cells using the FuGENE HD transfection reagent, according to the manufacturer's instructions. Briefly, 2 × 10 5 cells/mL were transfected with 5 μg DNA using FuGene HD, and the cells were passaged and cultured with 1 mg/mL Geneticin. Cell lysates were collected and H19 RNA levels were measured by qRT-PCR.
To construct expression vectors for human H19 short hairpin RNA (shRNA), a DNA fragment flanked by Bam HI and Hind III sites containing the sense target sequence for H19 (5′-TCA TCA GCC CAA CAT CAA A-3′), the hairpin loop sequence (5′-TAG TGC TCC TGG TTG-3′), and the antisense target sequence were synthesized and inserted into the pBAsi-hU6 Neo DNA vector. Similarly, the scrambled sequence (5′-TCT TAA TCG CGT ATA AGG C-3′) was used to construct the sham vector that served as a negative control. Transfections of the H19 shRNA (shH19) and scrambled shRNA (Sc) vectors were performed as described above.
Transfection of siRNA targeting H19
We used two types of siRNA targeting different sites in the H19 RNA: siH19-A (n272453) and siH19-B (n272446). The sense siRNA sequences of siH19-A and siH19-B were 5′-UCA UCA GCC CAA CAU CAA ATT-3′ and 5′-CCC UCU AGC UUG GAA AUG-ATT-3′, respectively. The cells were plated at a density of 2 × 10 5 cells in 35 mm dishes and transfected 24 h later with 5 nM of either siRNAs targeting H19 or Silencer negative control siRNA (siNeg) using TransITsiQUEST according to the manufacturer's protocol. To confirm the effective transfection of siRNA into cells, total RNA was prepared at 48 h after the transfection and H19 RNA levels were determined by qRT-PCR.
Cell proliferation assays
Cells were cultured in RPMI 1640 medium with 10% FBS at a density of 5 × 10 3 in 96-well plates followed by incubation for 24, 48, 72, or 96 h. The cells were then incubated with WST-8 cell counting reagent for 4 h. Optical density was measured using a plate reader (Bio-Rad Laboratories, Hercules, CA) at 450 nm.
Single-cell movement assay
To assess cell migration, a single-cell movement assay was performed [7] . Cells (5000 per well) were seeded onto fourwell glass-bottom dishes. Images of cell movement were captured every 5 min and monitored for 24 h by a Digital Eclipse TE 2000-E motorized inverted microscope (Nikon Insteck Co., Ltd). The total distance covered by individual cells (60 cells for each group) within 24 h was determined using Metamorph software 7.6 (Universal Imaging Corp. Ltd, Buckinghamshire, UK) according to the manufacturer's protocol.
Boyden chamber assay
A cell migration assay was also carried out using the Boyden chamber technique as previously reported [7, 19, 20] . Cell culture inserts (8 μm pore size and 6 mm in diameter) were used according to manufacturer's instructions. For PANC-1 and PANC-lung1 cells, at 12 h after placing 5 × 10 4 cells/500 μL onto the upper component of the inserts, the numbers of cells that had migrated through the membrane to the lower surface of the filter were counted in nine high-power fields ( × 200).
Intravenous implantation of PANC-1 cells in NOG mice
PANC-1 parental cells, Sc cells, or shH19 cells (1 × 10 6 cells in 100 μL PBS) were injected into the tail vein of 8-week-old male NOG mice (N = 3 for each cell line). Eleven weeks after injection, the animals were killed and the internal organs were excised and weighed.
To analyze the metastases histologically, the organs including the liver, lungs, heart, spleen, kidneys, adrenal glands, pancreas, stomach, intestine, and colon were fixed in 4% paraformaldehyde, embedded in paraffin wax, and cut into tissue sections at 4 μm thickness. The sections were stained with hematoxylin and eosin, and the serial sections were immunostained using a Histofine mouse stain kit with a mouse monoclonal antibody against HLA class I-A, B, and C. For analysis of the immunostaining results, we captured five images in each specimen at × 40 magnification and then measured the areas of positive cells using Image J software (NIH, Bethesda, MD).
H19 expression levels following the addition of anticancer drugs
Cells were plated in 24-well plates with growth medium. Each anti-cancer drug (100 μM gemcitabine, 5-FU, or abraxane) was administered the next day and then the cells were further cultured for 24 h. The cells were collected and qRT-PCR was performed as described above.
Statistical analysis
All quantitative data are presented as the means ± SEM. The Student's t-test or Dunnett's method for continuous variables, Mann-Whitney's U-test or Steel's method for nonparametric variables, and Fisher's exact probability test for categorical variables were used to examine significant differences. Spearman's correlation coefficient by rank test was used to compare H19 expression and ductal adenocarcinoma differentiation. Differences were considered significant when P < 0.05. Computations were performed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA) and Statcel 3 software (OMS Publishing, Inc., Saitama, Japan). 
Results
DNA microarray analysis of metastatic adenocarcinoma
To investigate the underlying mechanisms of metastasis of pancreatic adenocarcinoma, we performed a DNA microarray analysis and compared the gene expression patterns between human parental PANC-1 and lung metastasisderived PANC-lung1 cells. We identified 11 genes that were over 10-fold elevated in PANC-lung1 cells as compared with PANC-1 cells (Table 1) . Among these, H19 exhibited the second largest increase (82.4-fold) and represented the only non-protein coding gene. We further confirmed the H19 increase in PANC-lung1 cells using qRT-PCR analysis in triplicate. We subsequently focused on H19 in the following studies, because the roles of lncRNA in cancer metastasis have not been fully elucidated.
H19 expression in human pancreatic cancer tissues
First, we examined the localization of H19 in human pancreatic cancer tissues using a highly sensitive ISH technique. Dotted H19 signals were detected focally or diffusely in 23 of 139 invasive ductal carcinomas (17%, Table 2 ). In human PDAC tissues, H19 was strongly expressed in tumor cells forming alveolar or small ductal structures (Fig. 1a,b , arrows), whereas it was not expressed in the majority of well-differentiated adenocarcinoma cells (Fig. 1c) . H19 expression was positively correlated with a higher histological grade of ductal adenocarcinomas (P < 0.0001, Table 2 ). In normal pancreatic tissues, sparse dotted positivity of H19 was detected in the intercalated/intralobular ducts (arrows, Fig. 1d ), but not in the interlobular ducts, acini, and islets.
H19 expression in pancreatic cell lines
Next, we examined the H19 expression levels in nine PDAC cell lines and in two cell lines from normal pancreatic ductal epithelial cells. Of the nine PDAC cell lines, five showed higher expression levels of H19 than observed in the two normal pancreatic ductal epithelial cell lines (Fig. 2a) . We then examined the expression levels of H19 in several types of cell lines derived from PANC-1 cells. The cell lines established from subcutaneous tumors of PANC-1 cells (PANC-skin A and -skin B) showed similar H19 expression levels as the parental PANC-1 cells. Conversely, H19 expression levels were higher in cell lines established from liver and lung metastatic foci that developed consequent to splenic injection of PANC-1 cells (PANC-liver1, -liver2, -lung1, and -lung2) as compared with the levels in parental PANC-1 cells (Fig. 2b) . Furthermore, lung metastasis-derived PANC-1 cells showed higher H19 expression levels than liver-derived PANC-1 cells in each mouse (PANC-liver1 vs. PANC-lung1 and PANC-liver2 vs. PANC-lung2, respectively).
Cell behaviors of H19-overexpressing PANC-1 cells
To examine the effects of H19 on the growth and migration of pancreatic cancer cells, we overexpressed H19 in PANC-1 cells using an H19 expression vector (H19 cells) and also prepared empty vector-transfected PANC-1 cells as a control (EV cells). H19 expression levels in H19 cells were approximately 10-fold higher than those in wild-type (WT) and emty vector (EV) cells as determined by qRT-PCR analysis (Fig. 3a) . Using these cells, we examined the effects of enhanced expression of H19 on pancreatic cancer cell behaviors. Cell growth rates did not significantly differ between WT, EV, and H19 cells (Fig. 3b) . Next, we confirmed the effect of H19 on cell motility. H19 cells moved greater distances in comparison with EV cells (P < 0.01) (Fig. 3c) . In addition, in Boyden chamber assays, a significantly larger number of H19 cells migrated through the pores of the membrane compared with EV cells (P < 0.01, Fig. 3d ).
Effects of H19 silencing in PANC-1 cells on cell behaviors
Next, we suppressed H19 expression in PANC-1 cells using a shRNA that targeted the H19 transcripts. H19 expression was lower in H19 shRNA-transfected cells (shH19 cells) than in WT and scrambled sequence transfected shRNA (Sc) cells (Fig. 4a) .
The growth rates of shH19 cells were not altered compared with those of Sc cells (Fig. 4b) . In the single-cell movement assay, shH19 cells exhibited decreased motility in comparison with Sc cells (P < 0.05, Fig. 4c ). Significantly fewer migrated shH19 cells than Sc cells were observed using the Boyden chamber assay (P < 0.01, Fig. 4d ).
Effects of transient suppression of H19 in PANClung1 cells
We next sought to determine the effects of siRNAs targeting H19 RNA on the cell behaviors of PANC-lung1 cells. Two siRNAs targeting different sites of the H19 transcript (siH19-A and siH19-B) were used to silence H19 in PANC-lung1 cells, which exhibited the highest level of H19 expression in our study. An siRNA that does not bind to any human RNA was also transfected into PANC-lung1 cells as a negative control (siNeg). H19 RNA levels in siH19-A and siH19-B cells were decreased to approximately 10% of those in WT or siNeg cells (Fig. 5a) . H19 silencing did not impact the cell growth rates (Fig. 5b) . In contrast, the single cell movements of siH19-A and siH19-B cells were inhibited compared with those of WT and siNeg cells (siH19-A vs. siNeg, P < 0.01, Fig. 5c ). The Boyden chamber assay showed that the numbers siH19-A and siH19-B cells that had migrated through the membrane were significantly less than those of siNeg cells (P < 0.01, Fig. 5d ).
Metastatic ability of H19-silenced PANC-1 cells in immunodeficient mice
To assess the metastatic potential of H19-silencing in pancreatic cancer cells, we performed tail vein injections of PANC-1 cells, Sc cells, and shH19 cells into NOG mice. At 11 weeks post-injection, macroscopically visible tumors were observed in the liver, lungs, kidneys, and adrenal glands in each group of mice. WT and Sc cells formed larger numbers of macroscopically-visible fused tumors in the liver and lung, as compared with shH19 cells (Fig. 6a,c) . The liver-and lungto-body weight ratios were lower in shH19 cells than WT and Sc cells (Fig. 6b,d) , with the difference of liver-to-body weight ratio being statistically significant (P < 0.05). Histologically, human HLA class I positive-pancreatic cancer cells were focally localized in the liver and lungs of mice injected with shH19 cells, whereas WT and Sc cells proliferated diffusely in the liver and lung fields (Fig. 6b,d) . The metastatic areas in the liver were statistically lower following shH19 cell administration (P < 0.01, Fig. 6b ).
Discussion
Accumulated gene mutations in pancreatic cancer cells have been reported to correlate with distant metastasis using rapid autopsy [21] . However, detailed mechanisms of pancreatic cancer metastasis including metastasis-related proteins or RNAs have not been well clarified. In the present study, a microarray analysis was applied to investigate the different gene expression levels between parental and metastatic pancreatic cancer cells. Notably, the 3 molecules showing the greatest expression increase in metastasisderived pancreatic cancer cells showed enhancement of over 60-fold compared with parental cell expression. Cancer/testis antigen 1 and 2 represented the tumor cell antigens with the highest protein-coding gene expression in metastatic cancer cells and lncRNA H19 was the most increased RNA. The human H19 gene is located on chromosome 11p15.5 and produces a 2.3 kb RNA. H19 was originally discovered in a screen of a murine fetal liver cDNA library for clones containing RNA sequences that decrease after birth [22] . H19 is expressed in various tissues of the developing embryo but is repressed in all tissues except skeletal and cardiac muscle shortly after birth in both mice and humans [22] [23] [24] . H19 has also been reported to be reactivated during regeneration and carcinogenesis in adult tissues [6, 10] . H19 was expressed in bladder cancer [11] , glioma [12] , breast cancer [13] , gastric cancer [14] , pancreatic cancer [15] , hepatocellular carcinoma [16] , and prostate cancer [17] . In the present study we used bDNA ISH to assess H19 expression, which yields highly sensitive and specific signals through amplification by branched DNA technology in formalin-fixed, paraffin-embedded tissues [25] . Here, H19 was found to be expressed in the intercalated/intralobular ducts but not in the interlobular ducts in normal pancreatic tissues. Some researchers have indicated that the intercalated ducts are involved in pancreatic regeneration from toxic injury [26] . These findings suggest that H19 contributes to the normal and regenerative process of smallsized ductal cells during pancreatic inflammation. Conversely, Micha et al. [27] . reported that H19 was imprinted in the normal pancreas and in chronic pancreatitis and that loss of imprinting was observed in one of four pancreatic cancer tissues but was not associated with increased transcript levels. Ariel et al. [24] . reported that H19 was expressed in the acini and islets but not in the ducts in the pancreas of the human fetus; in addition, they observed no expression in four PDACs using ISH. In contrast, Scaiewicz et al. [28] . described that 65% of PDACs exhibited positive signals for H19 expression. In our study, using highly specific and sensitive bDNA ISH, H19 was expressed in 17% of PDACs and its expression was correlated with poorly-differentiated histological types, suggesting that H19 is associated with the aggressiveness of PDAC. Moreover, some proteins such as CD133 and ezrin are expressed in the intercalated ducts rather than interlobular large ducts and acini, as well as being overexpressed in PDAC [29, 30] . Accordingly, some researchers have considered that intercalated ducts may constitute the site of origin of PDAC [30] .
Pancreatic cancer is known to be a highly heterogeneous tumor type [31] . Recently, Moffitt et al. [32] . divided pancreatic cancer into two groups (basal-like and classical) by using a gene expression clustering technique. Notably, in a study incorporating The Cancer Genome Atlas (TCGA), H19 was highly expressed in a cluster including the largely basal-like subtype, which has worse outcome compared with another cluster that included the largely classical subtype [33] . Further research is therefore needed to clarify the relationship between H19 expression and pancreatic cancer heterogeneity.
H19 expression in metastatic cells was increased as compared with their parental pancreatic cancer cells. Furthermore, the H19 levels of lung metastasis-derived cells were higher than those of liver metastasis-derived cells. However, the expression levels of H19 were not changed between parental cells and pancreatic cancer cells established from skin-growing tumors after subcutaneous injection. These results suggest that H19 might contribute to the metastatic process in pancreatic cancer.
Accordingly, we next examined the function of H19 in pancreatic cancer. H19 has been reported to induce cell proliferation in breast [34] and gastric cancer cells [35] . H19 also enhanced the migration and invasion of bladder cancer cells [11] and glioma cells [12] . In contrast, some researchers have reported that H19 suppressed the migration and invasion of hepatocellular carcinoma [16] and prostate cancer cells [17] . These findings suggest that the function of H19 varies with the histopathological type of cancer. In the present study, the analysis of gain-and loss-of-function experiments in pancreatic cancer cells demonstrated that H19 did not influence cell proliferation but increased the cell migration ability, which is consistent with a recent report [15] . Furthermore, we found that suppression of H19 expression was associated with a drastic decrease in the metastatic potential of PANC-1 cells in an experimental metastasis model using NOG mice. These in vitro and in vivo results indicate that H19 has key roles in cell migration and metastasis formation in pancreatic cancer but does not directly impact cancer cell proliferation. Notably, in approximately 70% of patients with pancreatic cancer, metastasis is reported as a main cause of death owing to multiple organ failure as determined using autopsy cases [36] . Thus, the inhibition of pancreatic cancer cell motility via siRNA-mediated H19 suppression might indicate the potential effectiveness of exogenous administration of nucleic acid medicine as a novel therapy for pancreatic cancer. However, in this study we did not obtain data regarding a correlation between H19 expression and prognosis. From a RNA-Seq dataset of TCGA database, 4 (2.2%) of 178 sequenced cases exhibited upregulated expression of H19 with a median duration of disease-free survival of 5.81 months, compared with 17.05 months in cases without H19 upregulation.
With respect to pancreatic cancer treatment and H19 expression, we detected significant increases of H19 level in 5-FU-or abraxane-treated PANC-1 cells compared with non-treated cells (Supplementary Figure 1) . This is consistent with the results from a study using the breast carcinoma cell line MCF-7, wherein a subline (MCF-7/AdrVp cells) exhibiting the property of a multidrug resistance overexpressed H19 relative to the parental MCF-7 cell line [37] . A similar phenomenon was also noted in NCI-H1688, a lung carcinoma cell line with a multidrug resistance phenotype [37] . The increased expression of H19 in anticancer agent-treated PANC-1 cells therefore suggests that H19 may be associated with drug resistance in pancreatic carcinoma cells.
Our results from both in vitro and in vivo experiments suggest that H19 expression correlates with poorly differentiated cell types and promotes pancreatic cancer metastasis. The restricted expression in normal tissues vs. the elevated expression in some high-grade cancer and metastatic cancer cells suggests that H19 might represent a novel therapeutic target for the treatment of pancreatic cancer.
